home / stock / clls / clls articles

CLLS Articles, Cellectis S.A. - From 06/18/24

Stock Information
Company Name: Cellectis S.A.
Stock Symbol: CLLS
Market: NASDAQ
Website: cellectis.com
Menu
CLLS CLLS Quote CLLS Short CLLS News CLLS Articles CLLS Message Board
Get CLLS Alerts

News, Short Squeeze, Breakout and More Instantly...
Cellectis Upgraded to Buy: Here's Why | Benzinga

Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflect...
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications | Benzinga

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnolog...

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia | Benzinga

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology ...

Cellectis Reports Financial Results for First Quarter 2024 | Benzinga

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March...
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 | Benzinga

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering ...

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca | Benzinga

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 20...

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer | Benzinga

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering ...
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs | Benzinga

This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delive...

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs | Benzinga

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting | Benzinga

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneerin...
Previous 10 Next 10